Lack Of Ebola Patients In Liberia Leads Drug Developer To Halt Experimental Treatment Clinical Trial

New York Times: Ebola Drug Trial Is Halted for Lack of Patients
“A clinical trial in Liberia of a drug to treat Ebola has been halted because of a sharp decline in the number of people infected with the virus, and studies in West Africa of other potential treatments are also facing problems finding patients…” (Pollack, 2/1).

Reuters: Chimerix to stop participation in clinical studies of Ebola drug
“Drug developer Chimerix Inc. said it would stop participation in clinical studies of its Ebola drug, brincidofovir, citing a significant decrease in the number of new cases for the virus in Liberia…” (Sikka/Koppalla, 1/30).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.